The share price is up 72% over the past twelve months. Revenue has fallen every single year since 2021. Those two facts belong to the same company, and the gap between them is the whole story.
Viatris was born in November 2020 from the merger of Mylan and Pfizer’s Upjohn division, a deal that stitched together roughly 1,400 approved medicines and promised global scale. What it delivered instead was a shrinking top line, a debt pile larger than the company earns in a year, and a strategic identity crisis that took five years to resolve. The company that investors are now paying up for looks quite different from the one that opened for trading in 2020, and whether the transformation is real or merely promised is the question the filed numbers can help answer.
What the numbers say
Revenue has declined for four consecutive years, reaching $14.3 billion in fiscal 2025 against a peak of $17.8 billion in 2021, according to the 10-K filed for fiscal year 2025. The stock is priced at a level our data places in the 97th percentile of Viatris’s own history, meaning the market is paying as if a sharp profit recovery is already underway. The filed numbers show the recovery is not yet in the results. That gap, between what the price assumes and what the filings confirm, is where the tension lives.
How a Giant Became a Shrinking Thing
The merger logic was straightforward: combine Mylan’s generics machine with Upjohn’s off-patent branded drugs and sell the bundle to the world. Generic drug pricing, however, does not reward scale the way consumer goods do. Competitors multiply, prices fall, and the revenue that looked durable at signing erodes quarter by quarter. By 2022 the top line was already contracting, and management began a long series of divestitures: the biosimilars business went in 2022, and by October 2023 the over-the-counter, women’s healthcare, and active pharmaceutical ingredient businesses had been sold for roughly $3.6 billion, according to Cravath’s deal summary.
The money from those sales went mostly to debt reduction, which is the right use of it given what the balance sheet looked like. But selling assets to pay down debt is not the same as growing, and the revenue line reflects that plainly.
What management is now selling to investors is a different story: a specialty pharmaceutical company with an ophthalmology pipeline built through the 2023 acquisitions of Oyster Point Pharma and Famy Life Sciences, a CNS foothold in Japan through the October 2025 Aculys Pharma deal, and now, as of October 8, 2026, a $1.65 billion agreement to acquire Pacira BioSciences, adding branded non-opioid pain medicines. In March 2026, management announced a long-term target of five to six percent combined revenue growth annually through 2030, a striking ambition for a company that has not grown its top line since 2021.
The company is mid-pivot: the legacy business is still shrinking while the acquired pipeline is not yet large enough to show up in the consolidated totals.
What the Most Recent Quarter Actually Filed
The Q3 2026 report is not yet available; according to Market Chameleon’s earnings date confirmation, Viatris is scheduled to release those results on November 5, 2026. The most recent filed figures come from the 10-Q for the quarter ended June 30, 2026.
For Q2 2026, Viatris reported total revenues of $3.76 billion. The adjusted gross margin, meaning the share of each revenue dollar left after the direct cost of making the drugs, was 57.5%. That is a healthy margin for a generics-heavy business, suggesting the remaining portfolio earns real money on each sale. The company also generated $382 million in operating cash flow for the quarter, which matters because cash flow is harder to dress up than reported earnings.
The quarter produced a GAAP net loss alongside adjusted EBITDA that was roughly ten times larger. EBITDA, short for earnings before interest, taxes, depreciation, and amortization, strips out non-cash charges and financing costs to show the underlying operating engine. The gap between those two figures is almost entirely explained by amortization, the accounting charge Viatris takes each quarter as it writes down the value of drug patents it acquired through the Mylan-Upjohn merger. Those charges are real in an economic sense, but they are not cash leaving the building today.
The debt picture is the part that deserves the most attention. As of June 30, 2026, total debt stood at roughly $13.35 billion, per the 10-Q for Q2 2026, against annual EBITDA of around $3.1 billion, per the full-year 2025 press release. That means the debt pile is more than four years of operating earnings. The company’s own reported gross leverage ratio, which uses adjusted EBITDA and reflects debt repayment progress, has improved meaningfully. In Q2 alone, Viatris repaid a substantial slug of maturing debt. Progress is real. The load is still heavy.
Now add the Pacira deal: $1.65 billion in cash, to be funded at closing, which is expected before year-end 2026. Pacira generated roughly $746 million in revenue over the prior twelve months, per the deal announcement. The revenue contribution is real but modest relative to the purchase price, and the acquisition adds leverage at a moment when the company has been working hard to reduce it.
The Crowd Has Already Arrived
The mood, meaning what the market is currently paying, has run well ahead of the math, meaning what the filed fundamentals justify on their own. Our data puts the current price-to-sales ratio in the 92nd percentile of Viatris’s own history and the price-to-earnings ratio in the 97th percentile. These are not the multiples of a company priced for a slow recovery; they are the multiples of a company priced for a transformation that investors have already decided will succeed.
Several named analysts share that optimism. UBS analyst Ashwani Verma raised his analyst valuation estimate to $26 on October 5, 2026, per MarketBeat’s analyst tracker. Oppenheimer initiated coverage on September 23, 2026, with an “Outperform” grade and a $25 estimate. Leerink Partners initiated on September 9, 2026, with an “Outperform” grade and a $20 estimate. The average twelve-month estimate across a dozen analysts sits near $20.50, implying modest upside from the current tape price, but the range of estimates is wide, which is itself a signal that the outcome is genuinely uncertain.
Simply Wall St. pegged a fair value of $19.40 on October 8, 2026, calling the stock “modestly undervalued” at its then-price. That framing is reasonable if the transformation delivers. It is less comfortable if revenue keeps declining and the Pacira integration absorbs management attention and cash.
The honest answer is that the filed numbers cannot yet confirm the story the price is telling. IF the five-to-six percent annual revenue growth target management filed in March 2026 materializes through 2030 and adjusted gross margins hold near the Q2 2026 level of 57.5%, applying the decade-median price-to-sales multiple to that projected revenue base would produce an implied value range, a range that is not a forecast but an illustration of what the multiple arithmetic would require. IF revenue instead continues its four-year decline and new acquisitions contribute later than projected, the same arithmetic suggests the current valuation embeds little tolerance for shortfall. The Q3 filing on November 5 will be the next real data point, and it arrives before the Pacira deal closes, so it will show the core business on its own terms one more time.
Reading the Numbers
- $14.3 billion, full-year 2025 revenue (10-K filed for fiscal year 2025): what it is, the total amount customers paid Viatris for its drugs last year. What it means here: this is the fourth consecutive annual decline from the 2021 peak of $17.8 billion, a cumulative drop of roughly $3.5 billion in annual sales. In everyday terms, imagine a bakery that sold $178 worth of bread in its best year and now sells $143. The ovens still work; fewer people are buying.
- $13.35 billion, total debt as of June 30, 2026 (10-Q for Q2 2026): what it is, all money owed to lenders. What it means here: at roughly $3.1 billion in annual EBITDA, this is more than four years of operating earnings committed to creditors before a dollar reaches shareholders. A household earning $60,000 a year carrying $240,000 in debt faces the same arithmetic.
- 57.5%, adjusted gross margin, Q2 2026 (10-Q for Q2 2026): what it is, the share of each revenue dollar left after paying to manufacture the drugs. What it means here: for every $10 Viatris collects, about $5.75 remains to cover overhead, interest, and eventually profit. That is a solid margin for a generics business, suggesting the remaining portfolio is not being sold at distress prices.
- P/E in the 97th percentile of own history (our data): what it is, the price tag per dollar of reported earnings. A multiple is simply what buyers are paying today for each dollar of profit. What it means here: the market is paying as if earnings will grow sharply and quickly. A household paying $350 for a $1 annual return would need 350 years to break even if nothing changed.
- $1.65 billion, Pacira acquisition price (deal announcement, October 8, 2026): what it is, the cash Viatris agreed to pay for Pacira BioSciences. What it means here: Pacira’s revenue over the prior twelve months was roughly $746 million, so Viatris is paying more than twice that figure. The deal adds branded drugs, but it also adds leverage at a moment when debt reduction has been the stated priority.
Reading the numbers
$14.3 billion in full-year 2025 revenue, down from $17.8 billion in 2021. Revenue is simply the total cash customers paid Viatris for its drugs in a year. The number matters here because it has fallen every year since the merger closed, a cumulative loss of roughly $3.5 billion in annual sales. That persistent decline is the reason the stock spent years in the doldrums even as management described a transformation in progress. Until revenue stabilises and turns, the transformation is a forecast, not a fact.
$13.35 billion in total debt against roughly $3.1 billion in annual EBITDA. Debt is money owed to lenders; EBITDA is a shorthand for what the business earns from operations before financing costs and accounting write-downs. Dividing one by the other gives a leverage ratio of more than four times, meaning it would take more than four years of operating earnings just to retire the debt, with nothing left over for shareholders in the meantime. This number moves the story because the Pacira acquisition adds $1.65 billion of new borrowing at the exact moment the company has been publicly committed to bringing that ratio down. Whether the deal accelerates the transformation or delays the debt payoff is the central tension heading into the Q3 filing.
A price-to-earnings ratio in the 97th percentile of Viatris’s own history. A P/E ratio is the price an investor pays today for each dollar of annual profit. At this level, buyers are paying an extraordinary sum for every dollar the company currently earns. That is not a valuation built on today’s results; it is a bet that earnings will multiply quickly. The number matters here because the filed financials do not yet show that earnings surge. The gap between a 97th-percentile valuation and a four-year revenue decline illustrates the sensitivity of the current price to execution: under the filed growth targets the multiple would require rapid earnings expansion, while under a continued-decline scenario the same arithmetic would leave little cushion, the Q3 filing will provide the next data point on which path is materializing.
For the standing yardsticks on Viatris: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Viatris.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Viatris Q4 and full-year 2025 results press release (PR Newswire)
- Viatris Q2 2026 results press release (PR Newswire)
- Viatris-Pacira deal announcement (BioSpace)
- Viatris analyst valuation estimates (MarketBeat)
- Viatris divestitures summary (Cravath)
- Simply Wall St. fair value assessment, October 8, 2026
- Q3 2026 earnings date confirmation (Market Chameleon)
